Document registry — page 18
Every document the Institute has published, 1,631 in total, with its identifier, type, certainty rating and review date.
Documents
-
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low09 Mar 2026 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, is the effect of CJC-1295 maintained across the full duration of…
Low07 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low07 Mar 2026 -
Randomised, double-blind, active-controlled, phase 3 study of Mazdutide in type 2 diabetes and obesity over 52 weeks. The Institute holds no reported primary result for…
06 Mar 2026 -
Consultation on the draft monograph for Melanotan-II, which the assessment committee released for public comment before ratification. The draft grades the compound's…
05 Mar 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Liraglutide compared with its comparator?
High03 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and knee osteoarthritis over 68 weeks or longer. The Institute holds no reported…
03 Mar 2026 -
Phase 1 ascending dose, phase 1 study of Survodutide in cardiovascular and obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low03 Mar 2026 -
Randomised crossover, phase 1 study of Exenatide in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low03 Mar 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to…
Moderate02 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity over 68 weeks or longer. The Institute holds no reported primary result for this…
02 Mar 2026 -
Observational, phase 3 study of Survodutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low02 Mar 2026 -
Consultation on the draft of this methodological review, which registers the question: What can be concluded from a development programme that was discontinued, and how…
01 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low01 Mar 2026 -
Randomised crossover, phase 1 study of Semaglutide in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low01 Mar 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low28 Feb 2026 -
In the population defined for type 2 diabetes mellitus, is the effect of Exenatide maintained across the full duration of the contributing trials?
High27 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Maridebart cafraglutide in obesity over 72 weeks. The Institute holds no reported primary result for this…
27 Feb 2026 -
Consultation on the draft of CEI-MS-11, which specifies the performance a determination must achieve for physical quality and states what the resulting figure does not…
26 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in obesity and knee osteoarthritis over as stated in the parent protocol. The Institute holds…
Very low26 Feb 2026 -
In adults with obesity and moderate to severe obstructive sleep apnoea, what is the effect of a pharmacological weight-reducing agent on the apnoea–hypopnoea index?
Moderate25 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low23 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low23 Feb 2026 -
Peptides, SARMs, injectable oils and raw materials.
22 Feb 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Dulaglutide compared with the comparator…
High21 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in obesity over 72 weeks. Primary result: The Institute holds a headline result indicating a…
Moderate21 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low21 Feb 2026 -
Single-arm open-label, phase 3 study of Orforglipron in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low21 Feb 2026 -
Growth-hormone secretagogue, selective ghrelin receptor agonist (pentapeptide). Ipamorelin activates the ghrelin receptor on pituitary somatotrophs, producing growth-hormone release through a pathway distinct from and…
Low20 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low20 Feb 2026 -
In the population defined for inflammatory bowel disease and mucosal barrier disorders, what is the incidence of adverse events leading to discontinuation with…
Moderate19 Feb 2026 -
In the population defined for type 2 diabetes mellitus, is the effect of Semaglutide maintained across the full duration of the contributing trials?
High18 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low17 Feb 2026 -
Consultation on the draft monograph for Epithalon, which the assessment committee released for public comment before ratification. The draft grades the compound's…
16 Feb 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Orforglipron compared with the comparator used in its contributing trials on the anchor…
Moderate15 Feb 2026 -
Custom peptide synthesis and amino acids. Founded 1998. ISO 9001 and cGMP certified, 1,500+ employees, 200+ patents.
15 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in obesity over as stated in the parent protocol. The Institute…
Very low15 Feb 2026 -
Phase 1 ascending dose, phase 1 study of Retatrutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low13 Feb 2026 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in type 2 diabetes and obesity over as stated in the parent protocol. The Institute holds no…
Very low12 Feb 2026 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Petrelintide compared with its…
Low11 Feb 2026
page 18 of 41